DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris
Drug: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.

First Posted Date: 2024-01-16

Last Posted Date: 2025-03-21

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT06205407

Locations: 🇺🇸
Clinical Trials of Texas, LLC, San Antonio, Texas, United States

Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data

Active, not recruiting

Conditions: SARS-CoV-2
COVID-19 Vaccines

Interventions: Biological: Vaccination

First Posted Date: 2024-01-10

Last Posted Date: 2024-06-04

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06199934

Locations: 🇺🇸
Pfizer Global Headquarters, New York, New York, United States

A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07940367

First Posted Date: 2024-01-05

Last Posted Date: 2024-06-13

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT06190561

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

Phase 1

Active, not recruiting

Conditions: Pneumococcal Disease

Interventions: Biological: Multivalent Pneumococcal Vaccine - Formulation 1
Biological: Multivalent Pneumococcal Vaccine - Formulation 2
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological: Licensed pneumococcal comparator vaccine

First Posted Date: 2023-12-26

Last Posted Date: 2024-12-30

Lead Sponsor: Pfizer

Target Recruit Count: 418

Registration Number: NCT06182124

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
🇺🇸
Indago Research & Health Center, Inc, Hialeah, Florida, United States
🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States

and more 11 locations

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Phase 1

Active, not recruiting

Conditions: Grippe
Influenza
Vaccines

Interventions: Biological: pdmFlu vaccine
Biological: Placebo
Biological: Licensed influenza vaccine

First Posted Date: 2023-12-21

Last Posted Date: 2025-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 157

Registration Number: NCT06179446

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸
NYU Langone Health, New York, New York, United States

and more 1 locations

A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07293893
Drug: Placebo
Drug: Midazolam

First Posted Date: 2023-12-20

Last Posted Date: 2024-12-18

Lead Sponsor: Pfizer

Target Recruit Count: 88

Registration Number: NCT06177457

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
🇺🇸
Yale University/Magnetic Resonance Research Center (MRRC), New Haven, Connecticut, United States
🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ritlecitinib

First Posted Date: 2023-12-15

Last Posted Date: 2025-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06172348

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.

Withdrawn

Conditions: COVID-19
Coronavirus Disease 2019
Influenza

Interventions: Biological: COVID-19 Vaccine

First Posted Date: 2023-12-11

Last Posted Date: 2024-03-01

Lead Sponsor: Pfizer

Registration Number: NCT06163677

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

Phase 3

Recruiting

Conditions: Vitiligo

Interventions: Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg
Drug: Placebo

First Posted Date: 2023-12-08

Last Posted Date: 2024-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 400

Registration Number: NCT06163326

Locations: 🇺🇸
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
🇺🇸
Alpesh D. Desai, DO PLLC, Houston, Texas, United States
🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan

and more 71 locations

Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults

Phase 1

Completed

Conditions: Healthy Subjects
Healthy Participants

Interventions: Drug: Danuglipron

First Posted Date: 2023-12-01

Last Posted Date: 2024-10-21

Lead Sponsor: Pfizer

Target Recruit Count: 33

Registration Number: NCT06153758

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy